{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-003584","form_type":"8-K","ticker":"CNBX","cik":"0001343009","company_name":"CNBX Pharmaceuticals Inc.","filed_at":"2022-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.324008+00:00","generated_at":"2026-06-25T16:30:08.736653+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CNBX Pharma effects 1:120 reverse split and cuts authorized preferred to 5M shares","bullets":["Reverse stock split of 1:120 effective May 12, 2022; par value unchanged.","Authorized preferred shares reduced from 100,000,000 to 5,000,000.","Common stock now trades on OTCQB under new symbol CNBXD; new CUSIP 13764M209.","The reverse split was effected by filing a Certificate of Change with Nevada Secretary of State."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-003584","json":"https://secwatch.observer/filing/0001683168-22-003584.json","markdown":"https://secwatch.observer/filing/0001683168-22-003584.md","text":"https://secwatch.observer/filing/0001683168-22-003584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1343009/000168316822003584/0001683168-22-003584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1343009/000168316822003584/cnbx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T16:30:08.736653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}